Heart drug mavacamten targets rare blockage in thick heart muscle
NCT ID NCT07103655
First seen Jan 27, 2026 · Last updated May 21, 2026 · Updated 16 times
Summary
This study tests the drug mavacamten in 132 people with hypertrophic cardiomyopathy (thick heart muscle) that blocks blood flow in the middle to lower part of the heart. The goal is to see if the drug reduces the pressure buildup in the heart during a breathing maneuver over 36 weeks. Participants must have a confirmed diagnosis and meet specific thickness criteria for their heart walls.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.